VKTX Shorts Lag Peers as Analysts Stay Bullish Ahead of Q3 Print

VKTX carries one of the heaviest short positions in mid-cap biotech, yet the borrow market tells a less pressured story than the headline number suggests.

Short interest in Viking Therapeutics has climbed 16% over the past month to 23% of the free float, a level that ranks in the bottom 9th percentile of the ORTEX universe by short score rank. But borrow cost has dropped sharply over the same week, falling 28% to 0.56%, and availability has loosened considerably: at 107%, there are now roughly as many shares available to borrow as are already borrowed, well up from the 61% reading a week ago. The ORTEX short score has eased from 74.8 on October 12 to 72.7 by October 19, a modest retreat but still elevated territory.

Options positioning tells a different story from the shorts. Call volume is running well ahead of puts: the put/call ratio has dropped to 0.20, about 1.5 standard deviations below its 20-day average of 0.25, and close to the 52-week low of 0.16. That is not the profile of a market bracing for bad news; it points to investors leaning toward upside. The stock gained 6.6% on October 20 alone and is up 0.2% on the week, a notably weaker move than its closest correlated peers, which posted a median weekly gain of 3.6%.

Among those peers, VERA added 12.2% on the week and CTMX gained 8.0%, while DMAC rose 10.9%. VKTX's relative flatness despite Tuesday's sharp one-day bounce suggests the stock is being held back by something the peers are not carrying: specifically, a 23% short base and a market price of $26.71 that sits far below the analyst consensus target of $94.10.

That gap between price and consensus is the central tension heading into the print. Analyst opinion remains emphatically positive: UBS initiated coverage last week with a Buy and a $94 target, Canaccord Genuity lowered its target to $106 from $114 while keeping a Buy, and Truist Securities trimmed to $85 from $87 also maintaining Buy. The bull case rests on VK2735's phase 2 data showing up to 21.7% weight loss with durable maintenance and placebo-like tolerability, plus a $603 million cash balance the company says funds operations into 2028. The analyst recommendation divergence score ranks in the 92nd percentile, meaning the bullish skew is unusually strong relative to history.

Bears focus on execution risk in a market where Lilly's competing data has set a high bar for differentiation, and on the Ligand agreement that could generate up to $75 million per indication in milestone obligations plus royalties. The company reported a Q1 loss of $1.37 per share against a $0.98 consensus, and Viking's EPS momentum scores rank in the 33rd to 45th percentile range, reflecting the pre-revenue reality. CEO Brian Lian sold nearly $5 million in shares on July 29 alongside sales by the CFO and COO at prices around $33, levels the stock has since failed to reclaim.

The quarterly result will test whether the VK2735 programme timeline is intact and whether management's confidence in the 2028 cash runway leaves enough room for investors to price in a realistic path to phase 3 completion, given how much of the $94 consensus target depends on getting there cleanly.